News | Low-Intensity Pulsed Ultrasound May Restore Ovarian Function
A review suggests that low-intensity pulsed ultrasound (LIPUS) could become a new noninvasive treatment for restoring ovarian function in primary ovarian insufficiency (POI). It summarizes mechanisms and experimental progress and examines combination therapy.
POI is a complex endocrine disorder marked by premature follicle depletion, declining ovarian function, and reduced fertility. Hormone replacement therapy (HRT) can relieve menopausal symptoms but does not restore ovarian endocrine function and carries potential risks such as breast malignancy. Safe treatments acting directly on ovarian tissue are therefore a priority.
LIPUS uses mechanical stress, cavitation, and microstreaming to affect the cellular microenvironment. Experimental data show that it can regulate cell proliferation and apoptosis, suppress inflammation, and promote angiogenesis, improving local ovarian tissue function. These pathways align with key mechanisms of ovarian decline.
Animal and cell studies suggest potential benefits for follicle activation, ovarian microcirculation, and endocrine signaling. Combining LIPUS with hormone therapy, stem-cell treatment, or growth factors may increase benefits and reduce adverse effects of individual therapies.
Despite encouraging findings, large standardized human studies are needed to confirm safety, dosing, and long-term efficacy. Precise treatment windows and individualized regimens will be essential to avoid tissue injury.
The review positions LIPUS as a potential platform that could change POI treatment, not merely an adjunct. Advances in regenerative medicine and precision physical therapy may bring ovarian restoration into an era of noninvasive regulation.
News | Low-Intensity Pulsed Ultrasound May Restore Ovarian Function
News | Low-Intensity Pulsed Ultrasound May Restore Ovarian Function
A review suggests that low-intensity pulsed ultrasound (LIPUS) could become a new noninvasive treatment for restoring ovarian function in primary ovarian insufficiency (POI). It summarizes mechanisms and experimental progress and examines combination therapy.
POI is a complex endocrine disorder marked by premature follicle depletion, declining ovarian function, and reduced fertility. Hormone replacement therapy (HRT) can relieve menopausal symptoms but does not restore ovarian endocrine function and carries potential risks such as breast malignancy. Safe treatments acting directly on ovarian tissue are therefore a priority.
LIPUS uses mechanical stress, cavitation, and microstreaming to affect the cellular microenvironment. Experimental data show that it can regulate cell proliferation and apoptosis, suppress inflammation, and promote angiogenesis, improving local ovarian tissue function. These pathways align with key mechanisms of ovarian decline.
Animal and cell studies suggest potential benefits for follicle activation, ovarian microcirculation, and endocrine signaling. Combining LIPUS with hormone therapy, stem-cell treatment, or growth factors may increase benefits and reduce adverse effects of individual therapies.
Despite encouraging findings, large standardized human studies are needed to confirm safety, dosing, and long-term efficacy. Precise treatment windows and individualized regimens will be essential to avoid tissue injury.
The review positions LIPUS as a potential platform that could change POI treatment, not merely an adjunct. Advances in regenerative medicine and precision physical therapy may bring ovarian restoration into an era of noninvasive regulation.
Story source:
Collected online